Platinum Priority – EditorialReferring to the article published on pp. 834–840 of this issueThe Ongoing Challenges of Targeting the Androgen Receptor
Referring to the article published on pp. 834–840 of this issue
Section snippets
Conflicts of interest
Johann de Bono is employed by the Institute of Cancer Research, which has a commercial interest in abiraterone acetate. He has served as the chief investigator of the registration abiraterone, enzalutamide, and cabazitaxel phase 3 studies and has participated in advisory boards run by Janssen, Astellas, Sanofi, Takeda, and AstraZeneca.
Funding support
The authors are supported by a Cancer Research UK Centre grant, an Experimental Cancer Medicine Center grant, National Institute for Health Research Biomedical Research Center funding, and support from Movember, Prostate Cancer UK, and the Prostate Cancer Foundation.
References (11)
- et al.
Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
Cancer Treat Rev
(2015) - et al.
Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study
Eur Urol
(2016) - et al.
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Lancet Oncol
(2014) - et al.
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
Eur J Cancer
(2014) - et al.
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients
Eur Urol
(2015)
There are more references available in the full text version of this article.
Cited by (5)
Systemic treatment options for metastatic hormone-sensitive prostate cancer: Making sense of the data
2020, Current Opinion in UrologyTreatment patterns of prostate cancer with bone metastasis in Beijing: A real-world study using data from an administrative claims database
2019, Pharmacoepidemiology and Drug SafetySecond Brazilian consensus on the treatment of advanced prostate cancer: A SBOC-SBU-SBRT panel review
2019, International Braz J UrolAdvances in Receptor-Mediated, Tumor-Targeted Drug Delivery
2019, Advanced TherapeuticsProstate cancer, version 2.2019
2019, JNCCN Journal of the National Comprehensive Cancer Network
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.